Sarilumab is effective rapidly in ultrasound for patients with rheumatoid arthritis

• Published in: Clinical Rheumatology and Related Research Vol. 31; no. 1; pp. 41 - 47
• Main Authors: Kimura, Yuko, Yoshida, Shuzo
• Format: Journal Article
• Language: Japanese
• Published: The Japanese Society for Clinical Rheumatology and Related Research 30.03.2019; 一般社団法人 日本臨床リウマチ学会
• Subjects: efficacy; rheumatoid arthritis; sarilumab; ultrasound
• ISSN: 0914-8760; 2189-0595
• DOI: 10.14961/cra.31.41

  Objective: The purpose of this study was to examine short-term efficacy of sarilumab therapy in patients with rheumatoid arthritis（RA）.  Subjects and methods: Five patients with RA who underwent sarilumab treatment were assessed. 200 mg of sarilumab was administered SC by subcutaneous injection every 2 weeks for 12 weeks to patients with RA. Disease activity of RA was examined by DAS28-ESR and ultrasonography.  Results: All patients were women（mean age 64.0 ± 17.8, mean disease duration 16.5 ± 14.0 years）. DAS28-ESR was significantly improved（4.58 ± 0.65 at baseline to 2.90 ± 0.76 at 12 weeks p= 0.03）. Total power Doppler score was also significantly improved（10.6 ± 2.2 at baseline to 2.0 ± 1.9 at 12 weeks p= 0.0067）.  Conclusions: These findings suggested that sarilumab may lead to rapid improvement assessed by DAS28-ESR and ultrasound in patients with rheumatoid arthritis.